+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Biology and targeted therapy of gastrointestinal stromal tumors



Biology and targeted therapy of gastrointestinal stromal tumors



Tumor Research 40: 1-11



Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. Activating mutations of KIT or PDGF receptor alpha (PDGFRA) have been identified in the vast majority of GISTs. Most GISTs are sporadic and some kindred of familiar GIST with a germline mutation in KIT or PDGFRA have been reported. The inhibition of KIT or PDGFRA activity by the kinase inhibitor imatinib frequently results in dramatic clinical responses in advanced cases of GIST.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 011809364

Download citation: RISBibTeXText


Related references

Gastrointestinal stromal tumors (GIST)--a paradigm of successful targeted therapy of solid tumors. Acta Medica Croatica 60(5): 471-475, 2007

Gastrointestinal stromal tumors and the evolution of targeted therapy. Clinical Advances in Hematology and Oncology 3(8): 647-657, 2005

Molecular Targeted Therapy of Gastrointestinal Stromal Tumors. Current Cancer Drug Targets 11(6): 688-697, 2011

Molecular targeted therapy of gastrointestinal stromal tumors. Current Cancer Drug Targets 11(6): 688-697, 2011

Gastrointestinal stromal tumors: a paradigm for molecularly targeted therapy. Cancer Investigation 21(4): 553-563, 2003

Developments in targeted therapy of advanced gastrointestinal stromal tumors. Recent Patents on Anti-Cancer Drug Discovery 3(2): 88-99, 2008

Gastrointestinal stromal tumors: surgical treatment and targeted therapy. Khirurgiia 2018(12): 28-35, 2018

Gastrointestinal stromal tumors (GISTs): from science to targeted therapy. International Journal of Biological Markers 23(2): 96-110, 2008

Imatinib mesylate: a molecularly targeted therapy for gastrointestinal stromal tumors. Oncology 17(11): 1615-20; Discussion 1620, 1623, 1626 Passim, 2003

Gastrointestinal Stromal Tumors Respond to Tyrosine Kinase-targeted Therapy. Current Treatment Options in Gastroenterology 7(1): 13-17, 2004

Successes and limitations of targeted cancer therapy in gastrointestinal stromal tumors. Progress in Tumor Research 41: 51-61, 2015

Gastrointestinal stromal tumors A model for understanding solid tumor biology and development of targeted therapies, or just another low-hanging fruit?. Asia-Pacific Journal of Clinical Oncology 4(4): 185-187, 2008

Surgical outcomes of patients with gastrointestinal stromal tumors in the era of targeted drug therapy. Journal of Gastrointestinal Surgery 12(11): 2023-2031, 2008

Targeted therapy for gastrointestinal stromal tumors: current status and future perspectives. Cancer Metastasis Reviews 29(1): 151-170, 2010

Nursing implications of imatinib as molecularly targeted therapy for gastrointestinal stromal tumors. Clinical Journal of Oncology Nursing 9(2): 161-169, 2005